Key highlights of Q1 FY22 (ex-Natrol) Revenue from Operations at INR 5,702 Cr increased by 2.9% over corresponding period last year. During FY21, the Natrol business was divested. US formulations revenue remained largely flat on a YoY basis at INR 2,681.2 Cr Europe formulation revenue stood at INR 1,582.9 Cr, an increase of 19.7% over corresponding previous quarter Growth Markets registered a growth of 13.7% YoY to INR 329.3 Cr ARV revenue declined by 30.3% YoY to INR 296.4 Cr API revenue for the quarter was at INR 812 Cr vs. INR 780.1 Cr in the corresponding previous period EBIDTA before Forex and Other income stood at INR 1,209.4 Cr, an increase of 5.6 YoY; EBITDA margin for the quarter was 21.2% Research & Development (R&D;) spend at INR 358 Cr, 6.3% of revenues Received final approval for 4 ANDAs from USFDA including 3 injectables Net Profit stood at INR 770 Cr as against INR 707.3 Cr in the corresponding previous period Basic & Diluted EPS is INR 13.14 per share The Board declared an interim dividend of INR 1.50 per share. Commenting on the Company’s performance, Mr. N. Govindarajan, Managing Director of the company said: “The quarter’s performance reflected the resilience in our operations amidst the current challenging times. We remain focused on ensuring business continuity on the operations front and to resolve regulatory issues in some of our facilities. Our business is well prepared to navigate the journey towards profitable growth and we look forward to execute on our key growth pillars.” Result PDF